PMID- 9419060
OWN - NLM
STAT- MEDLINE
DCOM- 19980204
LR  - 20190724
IS  - 0022-510X (Print)
IS  - 0022-510X (Linking)
VI  - 152 Suppl 1
DP  - 1997 Oct
TI  - Factors influencing a patient's decision regarding riluzole: an early experience.
PG  - S80-1
AB  - Riluzole is the first drug to be approved in the United States for the treatment 
      of amyotrophic lateral sclerosis (ALS). During the first 8 months of the drug's 
      availability by prescription, its use was discussed with 46 patients with 
      probable or definite ALS as defined by the E1 Escorial criteria. Seventeen of the 
      patients (37%) chose to take riluzole while 29 (63%) refused. Increased duration 
      of symptoms, increased time since diagnosis, and participation in either the 
      insulin-like growth factor-1 (IGF-1) and brain-derived neurotrophic factor (BDNF) 
      trials were all associated with decreased likelihood of starting the drug. The 
      most common reason given for not wanting to take the medication was insufficient 
      benefit.
FAU - Rudnicki, S A
AU  - Rudnicki SA
AD  - University of Arkansas for Medical Sciences, Department of Neurology, Little Rock 
      72205-7199, USA. srudnicki@neurology.uams.edu
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Neuroprotective Agents)
RN  - 7LJ087RS6F (Riluzole)
SB  - IM
MH  - Aged
MH  - Amyotrophic Lateral Sclerosis/*drug therapy/physiopathology/*psychology
MH  - Costs and Cost Analysis
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neuroprotective Agents/adverse effects/economics/*therapeutic use
MH  - Riluzole/adverse effects/economics/*therapeutic use
MH  - Treatment Refusal
EDAT- 1998/01/07 00:00
MHDA- 1998/01/07 00:01
CRDT- 1998/01/07 00:00
PHST- 1998/01/07 00:00 [pubmed]
PHST- 1998/01/07 00:01 [medline]
PHST- 1998/01/07 00:00 [entrez]
AID - S0022-510X(97)00250-5 [pii]
AID - 10.1016/s0022-510x(97)00250-5 [doi]
PST - ppublish
SO  - J Neurol Sci. 1997 Oct;152 Suppl 1:S80-1. doi: 10.1016/s0022-510x(97)00250-5.